Sino Biopharmaceutical Li... (SBHMY)

PNK: SBHMY · Real-Time Price · USD

9.48

-0.82 (-7.96%)

At close: Apr 21, 2025, 3:37 PM

Sino Biopharmaceutical Balance Sheet Statement

Financials in CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Cash & Equivalents	9.45B	12.07B	10.57B	11.26B	11.91B	6.68B	4.19B	3.77B
Short-Term Investments	1.55B	4.86B	5.23B	5.17B	7.19B	2B	5.72B	4.81B
Long-Term Investments	25.18B	16.96B	18.97B	5.1B	-5.17B	1.07B	-3.94B	-3.4B
Other Long-Term Assets	3.78B	9.5B	7.5B	9.45B	9.87B	1.67B	6.13B	5.27B
Receivables	6.2B	4.64B	4.29B	2.91B	2.71B	2.92B	2.05B	2B
Inventory	1.99B	2.33B	1.94B	1.88B	1.66B	1.21B	918.82M	894.64M
Other Current Assets	912.71M	1.58B	1.25B	1.16B	630.76M	978.24M	710.33M	1.11B
Total Current Assets	23.81B	25.93B	23.5B	22.79B	24.91B	18.54B	13.78B	12.73B
Property-Plant & Equipment	9.91B	9.25B	8.52B	8.39B	6.44B	5.8B	4.27B	3.15B
Goodwill & Intangibles	928.94M	1.91B	1.71B	1.01B	909.99M	22.25B	308.18M	270.35M
Total Long-Term Assets	39.8B	38.13B	37.04B	24.42B	12.6B	31.24B	7.16B	5.65B
Total Assets	63.6B	64.06B	60.54B	47.21B	37.51B	49.78B	20.94B	18.38B
Account Payables	1.33B	1.64B	1.69B	1.95B	1.81B	1.83B	928.61M	826.73M
Deferred Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Short-Term Debt	11.14B	9.66B	6.52B	1.55B	666.75M	2.91B	741.31M	1.37B
Other Current Liabilities	3.35B	2.24B	1.82B	3.22B	2.06B	4.93B	1.25B	1.07B
Total Current Liabilities	22.61B	20.15B	15.35B	10.94B	8.12B	9.7B	5.69B	5.66B
Long-Term Debt	1.07B	3.93B	5.21B	12.36B	7.88B	507.07M	2.21B	1.68B
Other Long-Term Liabilities	1.46B	1.71B	1.94B	1.05B	n/a	1K	n/a	204.92K
Total Long-Term Liabilities	2.83B	5.97B	7.47B	13.85B	8.83B	1.55B	2.64B	2.05B
Total Liabilities	25.43B	26.12B	22.81B	24.79B	16.95B	11.25B	8.32B	7.71B
Total Debt	12.58B	13.98B	12.12B	14.21B	8.62B	3.49B	2.95B	3.05B
Common Stock	414.62M	414.9M	415.44M	415.89M	278.45M	278.85M	170.03M	165.92M
Retained Earnings	29.34B	28.36B	27.21B	13.6B	11.95B	n/a	8.47B	5.34B
Comprehensive Income	n/a	-15.39B	-13.39B	n/a	-9.83B	-462.85M	-587.27M	-848.18M
Shareholders Equity	30.47B	29.75B	30.29B	16.75B	31.11B	29.21B	9.21B	7.96B
Total Investments	25.82B	25.23B	25.17B	10.91B	2.02B	1.07B	1.78B	1.41B